What are the expected outcomes of adjuvant or neoadjuvant hormone therapy in patients with localised prostate cancer?
Adjuvant or neoadjuvant hormone therapy is not recommended for patients with low- or moderate-risk localised prostate cancer. 2.3 What is the optimal treatment for patients with T1-2 localised prostate cancer, accounting for level of risk and the risk of treatment-related harm? Based on the available evidence on the treatment of patients with localised prostate cancer, the working group cannot make any recommendations regarding which treatment is preferred. The working group also cannot recommend a specific treatment based on the reported adverse events and complications. The choice of treatment is determined after consultation with the patient whom the physician should inform thoroughly and as objectively as possible regarding the efficacy and toxicity of each treatment modality. The patient’s age and general condition are taken into account in the decision, particularly when considering the option of withholding treatment. 2.4 Nursing, supportive care, counselling, and communication
Related Questions
- Which patients with locally advanced prostate cancer will benefit from adjuvant or neoadjuvant hormone therapy with radiotherapy?
- Should hormone therapy be continued in patients who develop hormone-resistant metastatic prostate cancer (HRPC)?
- When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
